ResMed Inc. RMD
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.41B | 1.46B | 1.43B | 1.42B | 1.34B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.41B | 1.46B | 1.43B | 1.42B | 1.34B |
| Cost of Revenue | 536.45M | 594.13M | 532.58M | 536.28M | 514.76M |
| Gross Profit | 878.37M | 869.52M | 898.83M | 886.53M | 820.82M |
| SG&A Expenses | 284.20M | 293.36M | 279.80M | 275.70M | 271.15M |
| Depreciation & Amortization | -- | 18.80M | 19.10M | 19.57M | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 922.18M | 1.01B | 925.74M | 922.51M | 873.24M |
| Operating Income | 492.64M | 451.64M | 505.67M | 500.30M | 462.35M |
| Income Before Tax | 539.16M | 474.16M | 502.31M | 496.15M | 446.79M |
| Income Tax Expenses | 120.74M | 90.73M | 103.58M | 103.56M | 98.26M |
| Earnings from Continuing Operations | 418.41M | 383.43M | 398.73M | 392.59M | 348.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 418.41M | 383.43M | 398.73M | 392.59M | 348.54M |
| EBIT | 492.64M | 451.64M | 505.67M | 500.30M | 462.35M |
| EBITDA | 534.38M | 490.13M | 558.22M | 543.79M | 503.64M |
| EPS Basic | 2.93 | 2.65 | 2.74 | 2.69 | 2.38 |
| Normalized Basic EPS | 2.23 | 2.06 | 2.23 | 2.16 | 2.00 |
| EPS Diluted | 2.92 | 2.64 | 2.74 | 2.68 | 2.37 |
| Normalized Diluted EPS | 2.23 | 2.05 | 2.22 | 2.15 | 1.99 |
| Average Basic Shares Outstanding | 142.99M | 144.71M | 145.34M | 145.84M | 146.18M |
| Average Diluted Shares Outstanding | 143.41M | 144.98M | 145.72M | 146.37M | 146.90M |
| Dividend Per Share | 0.66 | 0.60 | 0.60 | 0.60 | 0.60 |
| Payout Ratio | 22.69% | 22.71% | 21.88% | 22.31% | 25.18% |